These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29546453)

  • 1. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
    Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
    Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
    Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
    J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
    Raje N; Woo SB; Hande K; Yap JT; Richardson PG; Vallet S; Treister N; Hideshima T; Sheehy N; Chhetri S; Connell B; Xie W; Tai YT; Szot-Barnes A; Tian M; Schlossman RL; Weller E; Munshi NC; Van Den Abbeele AD; Anderson KC
    Clin Cancer Res; 2008 Apr; 14(8):2387-95. PubMed ID: 18413829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database.
    Bejhed RS; Kharazmi M; Hallberg P
    Ann Pharmacother; 2016 Aug; 50(8):616-24. PubMed ID: 27179251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
    DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
    Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal model for medication-related osteonecrosis of the jaw with precedent metabolic bone disease.
    Kim JW; Tatad JCI; Landayan MEA; Kim SJ; Kim MR
    Bone; 2015 Dec; 81():442-448. PubMed ID: 26297440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
    J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw.
    Fung PL; Nicoletti P; Shen Y; Porter S; Fedele S
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):537-46. PubMed ID: 26299425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
    Wehrhan F; Hyckel P; Amann K; Ries J; Stockmann P; Schlegel K; Neukam F; Nkenke E
    Oral Dis; 2011 May; 17(4):433-42. PubMed ID: 21366807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
    Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V
    Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and management of osteonecrosis of the jaw secondary to bone-targeted therapy in patients with kidney cancer.
    Ripamonti CI; Lucchesi M; Giusti R
    Curr Opin Support Palliat Care; 2016 Sep; 10(3):273-80. PubMed ID: 27380219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of osteonecrosis of the jaw (ONJ) by medical ozone gas insufflation. A case report.
    Ripamonti CI; Maniezzo M; Pessi MA; Boldini S
    Tumori; 2012; 98(3):72e-75e. PubMed ID: 22825522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw.
    Allegra A; Mania M; D'Ascola A; Oteri G; Siniscalchi EN; Avenoso A; Innao V; Scuruchi M; Allegra AG; Musolino C; Campo S
    Biomed Res Int; 2020; 2020():9879876. PubMed ID: 32714991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
    Calvo-Villas JM; Tapia Torres M; Govantes Rodríguez J; Carreter de Granda E; Sicilia Guillén F
    Med Clin (Barc); 2006 Oct; 127(15):576-9. PubMed ID: 17153267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
    Higuchi T; Soga Y; Muro M; Kajizono M; Kitamura Y; Sendo T; Sasaki A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.